Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of ASP1893 in Participants With Metastatic or Locally Advanced CLDN6-positive Solid Tumors

NCT06681870 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.

NCT NCT06681870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06681870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of ASP1893 in Participants With Metastatic or Locally Advanced CLDN6-positive Solid Tumors
Lead sponsor
Astellas Pharma Global Development, Inc.
Phase
Phase 1
Overall status
Withdrawn
Start date
December 31, 2024
Completion date
March 31, 2029
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cldn6-positive solid tumor, endometrial cancer, metastatic or locally advanced solid tumor cancer, non-small cell lung cancer, ovarian cancer, testicular cancer